VRX - Valeant Pharmaceuticals International, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD

Valeant Pharmaceuticals International, Inc.

2150 St. Elzéar Boulevard West
Laval, QC H7L 4A8

IndustryDrug Delivery
Full Time Employees20,700

Key Executives

NameTitlePayExercisedYear Born
Mr. Joseph C. PapaCEO & Chairman10.72MN/A1955
Mr. Paul S. HerendeenExec. VP & CFO10.75MN/A1956
Ms. Christina M. AckermannExec. VP and Gen. Counsel2.04MN/A1965
Mr. J. Michael PearsonFormer Chief Exec. Officer11.97M60.51M1959
Mr. Osama A. EldessoukySr. VP, Controller & Chief Accounting OfficerN/AN/A1972
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Valeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.

Corporate Governance

Valeant Pharmaceuticals International, Inc.’s ISS Governance QualityScore as of March 1, 2018 is 9. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.